Action Potential Venture Capital

📣 NEWS ALERT 📣 With this funding we're transforming the stroke continuum of care by establishing Vivistim Therapy™ as the standard of care for chronic stroke recovery. 💪 "The MicroTransponder executive leadership team is building the company in a very thoughtful way to establish Vivistim Therapy™ as the standard of care for stroke survivors. We're excited by the combination of commercial excellence and the overwhelmingly positive clinical outcomes that show material improvements in stroke survivors' quality of life with Paired VNS™ Therapy." ~Casey Tansey, a USVP general partner and MicroTransponder board member. Tap here to view the press release in our news room and review safety information: https://qrcodes.pro/vbdPY7

Today we announced Saluda Medical raised $100 million financing round. Proceeds from the financing will be used primarily to advance the commercialization of the Evoke® System, the first commercial application of the Company’s proprietary closed-loop, dose-control neuromodulation platform. The Evoke® System is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. https://lnkd.in/gt3pe6Dq #KnowTheDose #ControltheDose #ClosedLoop #Sensing To learn more about the Evoke® System, visit: https://lnkd.in/gX6abP8Z Risks and Important Safety Info https://lnkd.in/d2XZ_Asn Rx Only The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.

Exciting news on our latest round of funding! 🎉 Big thanks to our investors, team, providers and patients for your continued support and dedication. https://lnkd.in/g-dUHnWG

Reimbursement News: Today the American Medical Association CPT Editorial Panel accepted new CPT Category I codes for #Barostim.   “The Category I code designation represents an important milestone for the company and is a testament to the increased adoption, safety, and effectiveness of Barostim as an important option for patients suffering from the debilitating symptoms of heart failure. We greatly appreciate the support and guidance that the Society of Vascular Surgery and American College of Cardiology provided throughout this process,” said Kevin Hykes, President and CEO of CVRx.   The codes are expected to be implemented on January 1, 2026.   Read the full press release: https://barost.im/3Agzdum

We're pleased to announce that Setpoint has received IDE approval from the FDA to study its proprietary neuroimmune modulation platform in people living with relapsing-remitting multiple sclerosis (RRMS). “We look forward to initiating this pilot study to advance SetPoint's platform in another therapeutic area,” said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. “The results from our studies in validated preclinical models of MS suggest that the SetPoint System has the potential to address the urgent unmet medical need for novel therapies that reduce demyelination and promote remyelination – providing new hope for people living with MS.” The pilot study will be initiated in 2025 and will enroll up to 60 patients across the United States. Dive into the details here: https://lnkd.in/g6ReKNkc #TheSetPointAdvantage #MultipleSclerosis #RRMS #MS #Autoimmune This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.

Major news: We are thrilled to announce that the RESET-RA study has successfully met its primary endpoint!  👏🎉 This morning, we announced positive topline results from this landmark clinical study highlighting that neuroimmune modulation using the SetPoint System demonstrates a clinical benefit in adults living with moderate-to-severe rheumatoid arthritis (RA). “We are thrilled with these results from the RESET-RA study as they highlight the potential of the SetPoint System for providing rheumatologists and their patients a safe and effective treatment alternative to current RA therapies,” said Murthy Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. “As next steps, we look forward to submitting the data for presentation at upcoming rheumatology and neurosurgical medical meetings and completing our premarket approval submission to the FDA.” Read the full announcement from today’s release: https://lnkd.in/eizkT-4t #TheSetPointAdvantage #RheumatoidArthritis #RA This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.

https://lnkd.in/g45DKpKk